ACC.24: Late-Breaking Science Video Collection
Published: 06 April 2024
-
Views:
4738
-
Likes:
7
-
Views:
4738
-
Likes:
7
-
Up Next -
23m 6sPart 2 | Session 4 Late-Breaker Discussion: The ARISE-HF Trial
-
5m 50s -
7m 49sPart 3 | Session 2 Zilbesiran in Patients With Hypertension: KARDIA-2 -
3m 40s -
7m 18s -
6m 40sPart 3 | Session 5 Chelation Therapy in Post-MI Pts with Diabetes: TACT2 -
6m 41sPart 3 | Session 6 Semaglutide in Patients with HfpEF, Obesity and Diabetes: STEP HFpEF -
5m 41sPart 3 | Session 7 Self-Expanding vs Balloon Expandable TAVR: The SMART Trial -
3m 37s -
4m 35sPart 3 | Session 9 Technology-Assisted Nonprescription Rosuvastatin: TACTiC -
4m 45sPart 3 | Session 10 Coronary Sinus Reducer in Refractory Angina: ORBITA COSMIC -
2m 30sPart 3 | Session 11 TAVI Vs SAVR in Patients with Severe Aortic Valve Stenosis: DEDICATE-DZHK6 -
4m 17s
-
6m 45sPart 4 | Session 1 Artificial Intelligence in Cardiology: What You Need to Know in 2024 -
6m 21sPart 4 | Session 2 Weight Loss Medications: What You Need to Know in 2024
-
Part 5 Coming Soon
-
43m 48sPart 1 | Session 1 ACC.24 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
28m 9sPart 1 | Session 2 What's Hot at ACC.24? Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen
-
22m 43sPart 2 | Session 1 Late-Breaker Discussion: The EMPACT-MI Trial Harriette Van Spall, Javed Butler
-
14m 7sPart 2 | Session 2 Late-Breaker Discussion: The AEGIS-II Trial Michael C Gibson, Harriette Van Spall
Overview
Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.
To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.
For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
More from this programme
Part 1
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24.
Part 2
Late-Breaker Discussion Series
Host, Dr Harriette Van Spall is joined by principal investigators for discussion on selected late-breaking trials.
Part 3
Expert Interviews
Expert Interviews conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.
Part 4
Highlights
Part 5
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
| 1 session | |
| Coming Soon | Watch now |
About the episode
ACC 2024 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) welcomes Principal Investigator Dr Gregg Stone (Icahn School of Medicine at Mount Sinai, New York, NY, US) to discuss the REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure (NCT03499236) (V-Wave Ltd).
The RELIEVE-HF trial aims to assess the safety and efficacy of a new device, the V-Wave Interatrial Shunt System, in improving clinical outcomes for heart failure patients regardless of their ejection fraction. This is a prospective, multi-center, 1:1 randomized trial that enrolled 605 participants with both HFrEF and HFpEF. Patients must have NYHA Class II, Class III, or ambulatory Class IV heart failure (HF).
The primary outcome measure is device related adverse events and effectiveness of hierarchical composite of death, heart transplant or LVAD implantation, HF hospitalisations, worsening HF events treated as an outpatient and change in KCCQ. Findings presented at ACC.24 demonstrated that transcatheter implantation of the V-Wave inter-atrial shunt was safe but did not reduce symptoms or improve heart failure patient's prognosis across 2 years across the full range of LVEF. Results from a pre-specified stratified analysis suggested that inter-atrial shunt implantation is beneficial in patients with reduced LVEF, and harmful in patients with preserved LVEF.
Recorded remotely from New York and Hamilton, 2024.
Support: This is an independent content produced by Radcliffe Cardiology.
Editor: Mirjam Boros
Videographer: Mike Knight, Tom Green
Faculty Biographies
Gregg Stone
Professor of Medicine, Professor of Population Health Sciences and Policy, and Director of Academic Affairs
Dr Stone is a leading expert in interventional cardiology and is one of the most widely cited researchers in science. He has served as the principal investigator for approximately 130 national and international multicentre randomised trials, has delivered thousands of lectures internationally, and has authored more than 2,500 book chapters, manuscripts and abstracts published in peer-reviewed literature.
Dr Stone is the Director of Academic Affairs for Mount Sinai Heart Health System, and Professor of Medicine and Professor of Population Health Sciences and Policy at The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine, at Mount Sinai, New York.
Dr Gregg Stone is an editorial board member of Interventional Cardiology: Reviews, Research, Resources (ICR3).
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Comments